In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
|Articles|April 27, 2022
- April 2022
- Volume 88
- Issue 4
Pet Peeves: April 2022
Brought to you by The Sassy Pharmacist
Advertisement
Spelling Bee Champion
When people spell their name instead of saying John Smith.
Coupon Clippers
When people give you manufacturer coupons at pick up.
Time Crunch
When people ask if we can get the medication ready and they’ll bring the prescription when they come to pick up, “to save time.”
What’s Bothering You?
Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We’ll share them here and online.
Articles in this issue
over 4 years ago
Case Studies: April 2022over 4 years ago
Generic Product News: April 2022over 4 years ago
OTC Cases: April 2022over 4 years ago
RX Product News: April 2022over 4 years ago
Bijuva From TherapeuticsMDover 4 years ago
Support Individuals Who Abuse Alcoholover 4 years ago
OTC Product News: April 2022over 4 years ago
Services to Improve Therapeutic Outcomes Improve Star Ratingsover 4 years ago
Worldwide Generics Market Will Exceed $507 Billion in 4 YearsAdvertisement
Related to this article
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
3
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
4
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
5